teplizumab
dorlixizumab
bispecific
Ab
antisynthetase
countercorrelated
zanolimumab
idiospecific
oportuzumab monatox
polyantibody
alacizumab
antipolyvalent
soravtansine
fontolizumab
-ab
polyvalent
-zumab
antinucleosome
carlumab
ocrelizumab
durvalumab
immunoprecipitant
cedelizumab
agonistic monoclonal antibody
presentation
biciromab
brentuximab
talizumab
sulesomab
mapatumumab
zolimomab
agglutinin
antigenomic
antisubstance
-axo-
immunospecific
ozoralizumab
evolocumab
samalizumab
tigatuzumab
heteroclitic
ipilimumab
vobarilizumab
immunoprobe
lucatumumab
conatumumab
patritumab
nofetumomab
hyperimmunized
-a-